Berinert (C1 esterase inhibitor (human) IV) / CSL Behring  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
NCT01467947 / 2010-024242-30: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Completed
4
46
Europe
Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
CSL Behring
Hereditary Angioedema Types I and II
10/14
10/14

Download Options